Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics ownership disclosure: FMR LLC (and Abigail P. Johnson in a related capacity) reports beneficial ownership of 2,879,481 shares of common stock, representing 12.6% of the class in an Amendment No. 1 to a Schedule 13G/A.
The filing lists sole dispositive power and, where applicable, sole voting power tied to the reported shares. Signatures are dated 05/05/2026.
Avalo Therapeutics is offering shares of its common stock and, in lieu of shares to certain investors, pre-funded warrants exercisable for common stock, subject to 4.99% (or, at holder election, 9.99%) ownership limits. The company reported positive Phase 2 topline results for abdakibart in HS and lists common stock on Nasdaq under AVTX. The prospectus describes underwriting arrangements, an underwriter option to purchase additional shares, intended use of proceeds to advance abdakibart into Phase 3, and a preliminary cash position of approximately $82.0 million as of March 31, 2026.
Avalo Therapeutics reported positive topline Phase 2 LOTUS data for abdakibart (AVTX-009) in moderate to severe hidradenitis suppurativa. The 253‑patient randomized, placebo-controlled trial met its primary endpoint, with HiSCR75 response rates of 42.2% and 42.9% at Week 16 versus 25.6% for placebo.
Key secondary measures, including HiSCR50, International HS Severity Score System (IHS4) and draining tunnel count, were statistically significant or numerically favorable, and responses were similar in patients with and without prior biologic use. Abdakibart was well tolerated, with treatment-emergent adverse event rates comparable to placebo and no neutropenia, serious or opportunistic infections. Avalo plans to advance abdakibart into a registrational Phase 3 program in HS.
Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan sold 16,915 shares of common stock in open-market transactions. He sold 8,458 shares on April 29, 2026 at an average price of $13.0925 and 8,457 shares on April 30, 2026 at an average price of $13.2261. The sales were executed under a Rule 10b5-1 trading plan adopted on November 12, 2025, with actual prices ranging from $12.61 to $13.54. Following these transactions, he directly holds 423 shares, down from 17,338 shares before the sales.
AVTX insider filed a Form 144 reporting a proposed sale of 16,915 restricted stock units. The filing lists Morgan Stanley Smith Barney LLC as the broker. It also reports executed 10b5-1 sales of 7,979 shares on 04/01/2026 for $133,770.33 and 7,980 shares on 04/02/2026 for $136,822.69.
Avalo Therapeutics, Inc. entered into a Milestone Buyout Option Agreement and amendment tied to its March 2024 acquisition of AlmataBio, Inc. The original $15 million contingent milestone payment, due upon dosing the first patient in a Phase 3 trial, has been restructured.
Avalo will pay $2.25 million to the former AlmataBio securityholders within five business days of April 26, 2026 and gains an option, exercisable within 90 days, to pay an additional $5.125 million in cash, common stock, or both, in full satisfaction of the milestone. If Avalo does not exercise this option, it would instead owe $12.75 million in cash or stock upon achievement of the Phase 3 dosing milestone.
Avalo Therapeutics, Inc. is holding a virtual 2026 Annual Meeting of Stockholders on June 2, 2026, for holders of 26,714,337 common shares as of April 6, 2026. Stockholders will vote on electing seven directors, approving a Second Amended and Restated 2016 Employee Stock Purchase Plan, and ratifying Ernst & Young LLP as independent auditor for 2026.
The updated employee stock purchase plan would keep 961,608 shares available and add an annual “evergreen” increase from 2027 through 2036, capped at the lesser of 1% of specified equity outstanding or 4,000,000 shares per year. The proxy also outlines Avalo’s board independence, committee structure, director compensation, and governance policies.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold the resulting shares in a planned transaction. On April 6, 2026, Doyle exercised options to acquire 3,970 shares of common stock at $12.65 per share, then sold all 3,970 shares in open-market trades at an average price of about $18.01, with individual trades ranging from $18.00 to $18.10. Following the sale, Doyle directly held 3,622 shares of common stock and 210,530 stock options. The filing notes these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, and that the underlying option vests over four years, with 25% vesting on July 15, 2025 and the remainder in equal monthly installments over the next three years.